Medexus Pharmaceuticals (TSE:MDP) Raised to “Strong-Buy” at Raymond James

Raymond James upgraded shares of Medexus Pharmaceuticals (TSE:MDP) from an outperform rating to a strong-buy rating in a research report sent to investors on Wednesday, MarketBeat.com reports. They currently have C$4.00 price objective on the stock. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at $0.03 EPS, Q1 2026 earnings at $0.23 EPS, Q3 2026 earnings at $0.22 EPS, Q4 2026 earnings at $0.23 EPS, FY2026 earnings at $0.89 EPS, FY2027 earnings at $0.88 EPS, FY2028 earnings at $0.80 EPS and FY2029 earnings at $0.77 EPS.

MDP has been the subject of a number of other research reports. Leede Financial set a C$8.25 price target on shares of Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research note on Monday, September 30th. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Two investment analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Strong Buy” and an average price target of C$5.25.

Medexus Pharmaceuticals Trading Down 0.7 %

Shares of MDP opened at C$4.04 on Wednesday. Medexus Pharmaceuticals has a 12-month low of C$1.47 and a 12-month high of C$4.24. The company has a market cap of C$99.10 million, a PE ratio of 80.80 and a beta of 1.96. The stock has a 50-day moving average price of C$2.77 and a 200-day moving average price of C$2.53.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.